Current Treatment

Examining Inflammation as a Common Factor in Theories of Rosacea Pathophysiology

By Dr. Joseph Bikowski

Joseph Bikowski, MD
Clinical Assistant Professor, Dermatology
Ohio State University
Columbus, Ohio
Director
Bikowski Skin Care Center
Sewickley, Pennsylvania

Rosacea is a common, chronic disorder affecting millions of patients annually. Some estimates report prevalence rates as high as 1 in every 20 Americans.1 While the signs and symptoms of rosacea have been established and documented, the exact pathophysiology of the disease has yet to be fully identified.1,2 Multiple theories have been suggested ranging from microbial causation to photodamage.2,3,4 However, no single etiologic source has been established. Without researched evidence of the etiology of rosacea, we must consider other available clues to help identify the underlying pathophysiology. The most reliable source of this information is derived from current treatment practices where it is believed that effective therapies for rosacea work by exerting anti-inflammatory effects.5,6,7 Therefore, it is necessary to examine the role of inflammation as a central causative factor of the signs and symptoms of rosacea.

The pathways of inflammation involved in rosacea have been documented to be from multiple physiologic sources. It is highly probable that these pathways work concomitantly to produce the common symptoms of rosacea such as inflammatory lesions, erythema, telangiectasias, phymatous changes, and ocular symptoms. This is supported by the fact that current therapies used to treat the disease work by interdicting multiple inflammatory pathways and yield improvement of varying degrees in each of the symptomatic areas.6,7,8, 9 Furthermore, the known anti-inflammatory properties of doxycycline (a common systemic therapy for rosacea) are closely correlated with the inflammatory mediators postulated to be responsible for the symptoms of rosacea.

Recent research has shown an increase of specific proinflammatory cytokines, including tumor necrosis factor (TNF-α) and interleukin (IL-1β), in biopsies of inflammatory lesions from acne patients.9 These cytokines trigger a chain of chemical responses in the body, including the release of certain matrix metalloproteinases (MMPs); specifically, MMP-1, -3, and -9.10,11 These MMPs are involved in collagen matrix degradation and inflammatory damage. The likely result is the development of papulopustular lesions. Owing to the similarities between these lesions in acne and rosacea, this evidence offers insight into the inflammatory nature of rosacea.

Two additional inflammatory mediators thought to incite the symptoms of rosacea are reactive oxygen species (ROS) and nitric oxide (NO). Clinical trial evidence reports that patients with severe rosacea have a reduced capacity to counter the negative effects of ROS; thus, experiencing an increased inflammatory response.11,12 This may also explain the connection between photodamage and rosacea since sun exposure is known to induce the release of ROS which subsequently activates MMPs.13 The role of NO involves vascular changes and is believed to be partially responsible for the erythema, edema, and telangiectatic symptoms of rosacea.11,13 Vasodilation plausibly results in vascular instability leading to increased vessel permeability, edema, and fixed vessels. This may worsen with increased sun exposure as an increase of NO in the keratinocytes has been linked with UVB rays.9

Substantiating each of the stated inflammatory mechanisms of pathophysiologic activity in rosacea is evidence that currently prescribed therapies do target these mechanisms. It is postulated that metronidazole and azelaic acid, both applied topically, reduce ROS and thereby decrease inflammation.6,7,15 Furthermore, doxycycline inhibits inflammation (directly and indirectly) by reducing the activity and/or expression of MMPs, TNF-α , IL-1β, NO, and ROS.8,11 These effects have been proven in anti-inflammatory doses of doxycycline which are devoid of antibiotic activity.8,16 Such activity results in improved integrity of the dermal tissue, reduced inflammation, and less vasodilation. Therapeutically, such effects appear to clinically reduce the numbers of inflammatory lesions, improve erythema, and help reduce the visibility and occurrence of telangiectasias. Hence, a comparison of available research regarding the pathophysiology of rosacea paired with the known activity of common treatments for this disease strongly point to inflammation as the central causative factor. This information is important to the development of future treatment options for rosacea as well as the appropriate selection of currently available treatments to ensure efficacious and safe therapies.

References

  1. Feldman SR, Hollar CB, Gupta AK, Fleischer AB Jr. Women commonly seek care for rosacea: dermatologists frequently provide the care.Cutis. 2001;68:156-160.
  2. Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005;352:793-803.
  3. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912.
  4. Dahl MV. Pathogenesis of rosacea.Adv Dermatol. 2001;17:29-45.
  5. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341.
  6. MetroGel 1% [package insert]. Fort Worth (TX): Galderma Laboratories, Inc; 2005.
  7. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies.J Am Acad Dermatol. 2003;48:836-845.
  8. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantbiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54:258-265.
  9. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512.
  10. Kang S, Cho S, Chung JH, et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor- B and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol. 2005;166:1691-1699..
  11. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12:12-26 .
  12. Oztas MO, Balk M, Ogus E, Bozkurt M, Ogus IH, Ozer N. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28:188-192.
  13. Jones D. Reactive oxygen species and rosacea. Cutis. 2004;74:17-20, 32-34.
  14. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci . USA 1996;93:14014-14019.
  15. Golden S, YP E, Lee W, AR. S, Masui M. The invitro effect of UVB on nitric oxide production in human telomerase immortalized keratinocytes. Poster presentation. Society of Investigative Dermatology. May 2003.
  16. Miyachi Y, Yoshioka A, Imamura S, Niwa Y. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86:449-453.
  17. Del Rosso JQ, Bikowski JB. Multicenter, double-blind, randomized, placebo-controlled, parallel-group trial results evaluating the effects of 40 mg doxycycline monohydrate controlled-release capsules in the treatment of rosacea. Poster presentation (P-164), 64th Annual American Academy of Dermatology Meeting, San Francisco, California, March 3-7, 2006 (submitted for publication).